We focus on both lower-grade gliomas, in which GAE is most prevalent over lifetime—particularly in tumors harboring isocitrate dehydrogenase (IDH) mutations—as well as high-grade gliomas where GAE remains a clinically relevant and complex issue. The gene discussed is IDH3A; the disease is central nervous system cancer.